Bifidobacterium showed promise in enhancing local anti-CD47 immunotherapy through STING signaling.Intratumoral/intravenous/oral administration of Bifidobacterium facilitated local anti-CD47 immunotherapy in a STING-IFN-dependent and T cell-dependent manner.Intratumoral injection of DMXAA similarly improved the anti-tumor efficacy of anti-CD47 therapy in nonresponder mice compared to Bifidobacterium. The gene discussed is STING1; the disease is neoplasm.